Discordant aPTT and anti-xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin;Valores discordantes de aPTT y anti-xa y los resultados en pacientes hospitalizados tratados con heparina no fraccionada intravenosa

Annals of Pharmacotherapy

Volumn 47, Issue 2, 2013, Pages 151-158

  Price, Elizabeth A ^a   Jin, Jing ^a   Nguyen, Huong Marie ^a   Krishnan, Gomathi ^b   Bowen, Raffick ^c   Zehnder, James L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stanford Center for Legal Informatics   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG INDICATION; FEMALE; HEART DISEASE; HEPARINIZATION; HOSPITAL PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; VENOUS THROMBOEMBOLISM;

EID: 84873965221     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R635     Document Type: Article

References (32)

1. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006;96:547-52.
2. Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998;158:1140-3.
3. Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996;75:734-9.
4. Shapiro GA, Huntzinger SW, Wilson JE 3rd. Variation among commercial activated partial thromboplastin time reagents in response to heparin. Am J Clin Pathol 1977; 67:477-80.
5. Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA. Interlaboratory variation in heparin monitoring: lessons from the Quality Management Program of Ontario coagulation surveys. Thromb Haemost 2010;104: 837-44. doi: 10.1160/TH10-02-0099
6. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998;122:782-98.
7. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008;133:141S-59S. doi: 10.1378/chest.08-0689
8. Baglin T, Barrowcliffe TW, Cohen A, Greaves M. Guidelines on the use and monitoring of heparin. Br J Haematol 2006;133:19-34. doi: 10.1111/j.13652141.2005.05953.x
9. Cuker A, Ptashkin B, Konkle BA, et al. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. J Thromb Haemost 2009;7:80-6. doi: 10.1111/j.1538-7836.2008.03224.x
10. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56.
11. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012;32:546-58. doi: 10.1002/j.1875-9114.2011.01049.x
12. Ignjatovic V, Summerhayes R, Gan A, et al. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate? Thromb Res 2007;120:347-51. doi: 10.1016/j.thromres.2006.10.006
13. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4. doi: 10.1111/j.1538-7836.2005.01204.x
14. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977;49:171-84.
15. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7. doi: 10.1056/NEJM197208172870703
16. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weightbased heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119:874-81.
17. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14. doi: 10.1056/NEJM198610303151801
18. Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996;156:1677-81.
19. Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999;159:2029-32.
20. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997;157:2562-8.
21. Morabia A. Heparin doses and major bleedings. Lancet 1986;1:1278-9.
22. Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-13.
23. Zidane M, Schram MT, Planken EW, et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice. Arch Intern Med 2000;160:2369-73.
24. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003;107: 2884-8. doi: 10.1161/01.CIR.0000077530.53367.E9
25. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-95.
26. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest 2008;133:257S-98S. doi: 10.1378/chest.080674
27. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4. doi: 10.1056/NEJM199005033221802
28. Coon WW, Willis PW 3rd. Hemorrhagic complications of anticoagulant therapy. Arch Intern Med 1974;133:386-92.
29. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Aging and heparin-related bleeding. Arch Intern Med 1996;156:857-60.
30. Yett HS, Skillman JJ, Salzman EW. The hazards of aspirin plus heparin. N Engl J Med 1978;298:1092.
31. Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 2011;45:861-8. doi: 10.1345/aph.1Q161
32. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e24S-43S. doi: 10.1378/chest.11-2291